Home Cart Sign in  
Chemical Structure| 180977-34-8 Chemical Structure| 180977-34-8

Structure of FTI-277 HCl
CAS No.: 180977-34-8

Chemical Structure| 180977-34-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FTI-277 HCl is an inhibitor of farnesyl transferase (FTase) and a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling.

Synonyms: FTI-277 hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FTI-277 HCl

CAS No. :180977-34-8
Formula : C22H30ClN3O3S2
M.W : 484.07
SMILES Code : CSCC[C@@H](C(OC)=O)NC(C1=CC=C(NC[C@@H](N)CS)C=C1C2=CC=CC=C2)=O.[H]Cl
Synonyms :
FTI-277 hydrochloride
MDL No. :MFCD28385886
InChI Key :PIAFFJUUNXEDEW-PXPMWPIZSA-N
Pubchem ID :88309922

Safety of FTI-277 HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of FTI-277 HCl

GPCR

Isoform Comparison

Biological Activity

Target
  • Transferase

    FTase, IC50:500 pM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human mesenchymal stem cells (MSC) 5 μM and 10 μM 1 week and 3 weeks FTI-277 significantly affected osteoblast differentiation (approx. -50±10%) and function (approx. -60±15%), with a higher inhibitory effect at 10 μM. Alendronate reversed the inhibitory effect of FTI-277. PMC3051383
Human mesenchymal stem cells (MSC) 5 μM and 10 μM 2 weeks Assessed the effect of FTI-277 on HDJ-2 and prelamin A, finding that FTI-277 inhibited farnesylation of both proteins, with a dose-dependent increase in unfarnesylated protein levels. PMC3051383
HELN cells 10 µM 24 hours In HELN cells, FTI-277 and GGTI-298 stimulated basal transcriptional activity by 3.6-fold and 2.4-fold, respectively, in the absence of E2. In the presence of E2, FTI-277 and GGTI-298 further enhanced transcriptional activity by an additional 2.2-fold and 1.6-fold, respectively. PMC1064103
MCF-7 cells 10 µM 24 hours FTI-277 significantly enhanced E2-induced transcriptional activity. In the absence of E2, FTI-277 and GGTI-298 stimulated basal transcriptional activity by 8.4-fold and 3.9-fold, respectively. In the presence of E2, FTI-277 and GGTI-298 further enhanced transcriptional activity by an additional 4.1-fold and 2.5-fold, respectively. PMC1064103
ESC-derived VEGFR2+ cells 3 μM 4 days Under low-density culture conditions, FTI-277 significantly reduced PECAM1+ colony numbers and increased αSMA+ colonies, indicating specific inhibition of endothelial differentiation. PMC2287293
MCF7 breast cancer cells 5 μM 48 hours Combined use of FTI-277 and IPA3 did not significantly inhibit cell proliferation PMC3765434
A549 lung cancer cells 5 μM 48 hours Combined use of FTI-277 and IPA3 significantly inhibited cell proliferation PMC3765434
HT29 colon cancer cells 5 μM 48 hours Combined use of FTI-277 and IPA3 significantly inhibited cell proliferation PMC3765434
A375MM melanoma cells 5 μM or 15 μM 48 hours FTI-277 treatment did not affect PAK protein levels but increased nuclear PhoPAK clusters PMC3765434
HeLa cells 5 μM or 15 μM 48 hours After 48 h of FTI-277 treatment, PAK and PhoPAK signals significantly increased PMC3765434
SH-SY5Y cells 100 nM 48 hours Reduced the abundance of membrane-associated UCH-L1 (UCH-L1M), decreased α-synuclein levels, and increased cell viability PMC2651203
MCF-7 cells 10 μM 48 hours To evaluate the effect of FTI-277 on cell proliferation, results showed that FTI-277 treatment significantly inhibited the proliferation of MCF-7 cells. PMC7291698
4T1 cells 10 μM 48 hours To evaluate the effect of FTI-277 on cell proliferation, results showed that FTI-277 treatment significantly inhibited the proliferation of 4T1 cells. PMC7291698
67NR cells 10 μM 48 hours To evaluate the effect of FTI-277 on cell proliferation, results showed that FTI-277 treatment significantly inhibited the proliferation of 67NR cells. PMC7291698
ESC-derived VEGFR2+ cells 1 μM 48 hours FTI-277 added within 3 hours post-VEGF-A stimulation suppressed endothelial differentiation, but no effect when added after 6 hours, demonstrating time-dependent inhibition. PMC2287293
B16F10 melanoma cells 10 or 20 μM 48 hours FTI-277 did not enhance membrane FasL expression PMC2134904
Human bronchial mesenchymal fibroblasts 10 μM 48 hours To investigate the effect of FTI-277 on TGFβ1-induced fibronectin expression; results showed no significant inhibition of fibronectin accumulation PMC3173339
MCF-7 cells 5.9 nM 5 days To evaluate the inhibitory effects of FTI-277 in combination with different anti-estrogens on MCF-7 cell proliferation. Results showed that FTI-277 combined with Tam had an additive effect, while combinations with ICI182,780 or PBPE exhibited synergistic effects. PMC1410750
CNE1 cells 1 μM 72 hours FTI-277 in combination with cisplatin slightly enhanced cytotoxicity in NPC cells with medium CENP-F expression PMC2944187
HONE1 cells 1 μM 72 hours FTI-277 in combination with cisplatin significantly enhanced cytotoxicity in NPC cells with high CENP-F expression PMC2944187
Murine bone marrow-derived mast cells 5 μM 72 hours Inhibition of Ras isoprenylation significantly reduces mast cell degranulation, cytokine production, and migration PMC7655736
3T3-L1 cells 20 µM(first 24 h), then 2.5 µM (next 7 days) 8 days To investigate the effect of FTI-277 on adipogenesis in 3T3-L1 cells. Results showed that FTI-277 increased the number of mature adipocytes, but when combined with non-farnesylated prelamin A accumulation, it reduced the expression of adipogenic genes. PMC10816192
CHO-K1 cells 1 μM 8 hours An 8 h treatment with 1μM FTI-277 led to an increase in p27 expression in cells that were selected before analysis for H-2Kk expression on magnetic beads conjugated to a monoclonal antibody against H-2Kk. PMC1299091
HeLa cells 1 μM 8 hours Addition of FTI-277 resulted in a 10- to 20-fold increase in LucF translation with a reporter containing the R17-binding site. PMC1299091
SK-Hep1 cells 1 μM 8 hours FTI-277 prevents the membrane association of the CAAX motif and thus increases the cytoplasmic levels of the eIF4G fusion protein, which is then capable of inducing translation of the second cistron of a bicistronic messenger RNA containing an R17-binding site in its intercistronic space. PMC1299091
COS-7 cells 100 nM Decreased the amount of transfected WT UCH-L1M PMC2651203

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse E6.75 whole-embryo culture model In vitro culture medium 10 μM Single dose, cultured for 3 days FTI-277 treatment diminished PECAM1+ vessels in yolk sacs, with decreased PECAM1 and VE-cadherin mRNA levels but unchanged αSMA expression, suggesting suppression of vascular development. PMC2287293
Mouse Dopaminergic neurons in midbrain mixed primary cultures Added to culture medium 100 nM Single treatment, duration not specified Reduced α-synuclein toxicity PMC2651203
Mice HBV transgenic mice Intraperitoneal injection 50 mg/kg/day Once daily for 7 days FTI-277 and FTI-2153 were both highly effective at clearing HDV viremia PMC166292

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.33mL

2.07mL

1.03mL

20.66mL

4.13mL

2.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories